CompletedNCT03465787
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
Researchers compared Lurasidone HCL 160 mg and Quetiapine XR 600 mg to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 19–75South Korea
Understand this study
What did researchers investigate?
Researchers compared Lurasidone HCL 160 mg and Quetiapine XR 600 mg to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 19 years to 75 years. Other eligibility criteria applied.
- Listed locations
- SeoulSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: April 9, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 210
- Sponsor
- Bukwang Pharmaceutical
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- South Korea
- Age range
- From 19 Years to 75 Years
- Official registry ID
- NCT03465787
- Official title
Show the full official title
A Phase 3 Randomized, Double-Blind, Active-controlled Study to Evaluate the Efficacy and Safety of Lurasidone in Acutely Psychotic Patients With Schizophrenia
Get this study by email
Recruitment & locations
CompletedSeoul
Questions about this study
What did researchers investigate?
Researchers compared Lurasidone HCL 160 mg and Quetiapine XR 600 mg to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Bukwang Pharmaceutical, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone HCL 160 mg and Quetiapine XR 600 mg.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 19 years to 75 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA
A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate